Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.57 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7289886 | 0.87 | THRA (0.54) | PLA2G4BTHRBTHRATSHR | |
| SCHEMBL19750764 | 0.86 | PLA2G2A (0.51) | SMPD1PLA2G4BTHRBTHRAPLA2G2A | |
| SCHEMBL14459972 | 0.86 | RAB9A (0.47) | KMT2ANR1H4POLBALOX12 | |
| SCHEMBL3683047 | 0.85 | TP53 (0.57) | PLA2G4BTHRBTHRATSHR | |
| SCHEMBL3067042 | 0.82 | RARB (0.60) | PLA2G4BTHRBTHRATSHR | |
| SCHEMBL7271786 | 0.82 | TP53 (0.53) | PLA2G4BTHRBTHRATSHR | |
| SCHEMBL7280580 | 0.82 | RARB (0.60) | PLA2G4BTHRBTHRATSHR | |
| SCHEMBL878923 | 0.81 | HPGD (0.52) | PLA2G4BTHRBTHRAKMT2APOLB | |
| SCHEMBL17961074 | 0.79 | SMPD1 (0.68) | SMPD1PLA2G4BTHRBTHRAKMT2A | |
| SCHEMBL17961053 | 0.79 | SMPD1 (0.68) | SMPD1PLA2G4BTHRBTHRAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | SMPD1 144/4885PLA2G4B 883/4885THRB 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.